Lenacapavir
Lenacapavir Basic information
- Product Name:
- Lenacapavir
- Synonyms:
-
- GS-6207
- Lenacapavir
- 1H-Cyclopropa[3,4]cyclopenta[1,2]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-
- 13C,2H3]-Lenacapavir , isomeric mixture
- MT-4,Inhibitor,antiretroviral,Lenacapavir,inhibit,GS 6207,capsid,Human immunodeficiency virus,HIV,GS6207,HIV-1,PBMCs
- 1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-
- 13C,2H3]-Lenacapavir (Major),isomers mixture
- N-((S)-1-(3-(4-Chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide
- CAS:
- 2189684-44-2
- MF:
- C39H32ClF10N7O5S2
- MW:
- 968.28
- Product Categories:
-
- API
- Mol File:
- 2189684-44-2.mol
Lenacapavir Chemical Properties
- Density
- 1.62±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 250 mg/mL (258.19 mM)
- form
- Solid
- pka
- 4.63±0.30(Predicted)
- color
- White to light yellow
Lenacapavir Usage And Synthesis
Description
HIV-1 capsid inhibitor GS-6207 (lenacapavir) is a drug being developed by Gilead Sciences, Inc. It is a first-in-class, oral HIV-1 capsid inhibitor.
Uses
Lenacapavir can be useful in capsid inhibition in multidrug-resistant HIV-1 infection.
Application
Lenacapasvir was first approved in the European Union in 2022 for use in combination with other antiretroviral drugs to treat multidrug-resistant adults with HIV and those who are unable to establish a suppressive antiviral regimen. Subsequently, the drug also received similar approvals in Canada and the United States. Lenacapasvir is available as an oral and injectable therapy and is a long-acting, extended-release drug for the treatment of HIV-1. When used in combination with other antiretroviral drugs, it may only need to be administered once every 6 months, aiming to improve patient compliance and medication adherence.
Mechanism of action
Lenacapasvir works by inhibiting the HIV-1 capsid protein, a protein shell that encapsulates the viral genetic material and is involved in multiple stages of the HIV life cycle. Lenacapasvir is the first drug approved to inhibit the HIV-1 capsid, providing a new treatment option for adults with multidrug-resistant HIV infection.
IC 50
HIV-1
LenacapavirSupplier
- Tel
- 18915538011; 18915538011
- liwei@boyanpharma.com
- Tel
- 13656237714 13656237714;
- xiaokunfu@kyyykj.com
- Tel
- 19353112242
- 1816280386@qq.com
- Tel
- hanfangpharma@126.com; 18616537568
- hanfangpharma@126.com
- Tel
- 13953971485
- 2199605322@qq.com